Search

Search Constraints

You searched for: Author/Creator Atzori, Francesco

Search Results

1. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. Issue 1 (27th February 2019)

2. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. (March 2020)

3. Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study. (22nd February 2019)

4. Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis. Issue 4 (July 2014)

5. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. (1st January 2020)

6. Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. (22nd March 2018)

7. GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. (October 2021)

8. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). (May 2021)

9. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. (17th October 2018)

10. Male Breast Cancer: Clinical Features and Multimodal Treatment in a Retrospective Survey Analysis at Italian Centers. Issue 5 (September 2013)